Suppr超能文献

调强放疗治疗 T4 期鼻咽癌的有效性和毒性。

Effectiveness and toxicities of intensity-modulated radiation therapy for patients with T4 nasopharyngeal carcinoma.

机构信息

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.

出版信息

PLoS One. 2014 Mar 7;9(3):e91362. doi: 10.1371/journal.pone.0091362. eCollection 2014.

Abstract

OBJECTIVE

To evaluate the effectiveness and toxicities in T4 nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT) combined with chemotherapy.

METHODS

This is a retrospective analysis of 81 patients treated with intensity-modulated radiotherapy (IMRT). All the primary tumors were attributed to T4 stage according to the AJCC2010 staging system. And the distribution of disease by N stage was N0 in 13.6%, N1 in 30.9%, N2 in 37%, and N3 in 18.5%. Cisplatin-based chemotherapy was offered to all patients. Radiotherapy-related toxicities were graded according to the Acute and the Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group (RTOG) scoring criteria. Chemotherapy-related toxicities were graded by National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Prognostic factors were assessed by univariate analysis.

RESULTS

With a median follow-up of 37 months, 12 patients experienced local regional failure and total distant metastasis occurred in 18 patients, representing the major mode of failure. Ten patients died. Among them, 70% died of distant metastasis. The 3-year actuarial rates of local failure-free survival (LFFS), regional failure-free survival (RFFS), distant failure-free survival (DFFS), overall survival (OS), and progression-free survival (PFS) were 83.8%, 97.4%, 81.3%, 90%, and 69.7%, respectively. Acute and late toxicities were mild or moderate.

CONCLUSIONS

IMRT provides excellent local-regional control for T4 NPC. Distant metastasis remains the major cause of treatment failure. Further explorations of the sequence and regimen of systemic therapy are needed in the future.

摘要

目的

评估调强放疗(IMRT)联合化疗治疗 T4 期鼻咽癌(NPC)的疗效和毒性。

方法

这是一项回顾性分析了 81 例接受调强放疗(IMRT)治疗的患者。所有原发性肿瘤均根据 AJCC2010 分期系统归为 T4 期。疾病的 N 分期分布为 N0 占 13.6%,N1 占 30.9%,N2 占 37%,N3 占 18.5%。所有患者均接受顺铂为基础的化疗。放疗相关毒性根据放射治疗肿瘤学组(RTOG)评分标准的急性和晚期放射发病率评分标准进行分级。化疗相关毒性根据国家癌症研究所常见毒性标准(NCI-CTC)版本 3.0 进行分级。采用单因素分析评估预后因素。

结果

中位随访 37 个月,12 例患者出现局部区域失败,18 例患者出现远处转移,为主要失败模式。10 例患者死亡。其中,70%死于远处转移。3 年局部无失败生存率(LFFS)、区域无失败生存率(RFFS)、远处无失败生存率(DFFS)、总生存率(OS)和无进展生存率(PFS)的 3 年累积率分别为 83.8%、97.4%、81.3%、90%和 69.7%。急性和晚期毒性为轻度或中度。

结论

IMRT 为 T4 NPC 提供了优异的局部区域控制。远处转移仍然是治疗失败的主要原因。未来需要进一步探索全身治疗的顺序和方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d919/3946722/6719ef2d551c/pone.0091362.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验